logo
US judge says HHS layoffs were likely unlawful and must be halted

US judge says HHS layoffs were likely unlawful and must be halted

PROVIDENCE, R.I. (AP) — A federal judge has ruled that the recent mass layoffs at the U.S. Health and Human Services were likely unlawful and ordered the Trump administration to halt plans to downsize and reorganize the nation's health workforce.
U.S. District Judge Melissa DuBose in Rhode Island granted the preliminary injunction sought by a coalition of attorneys general from 19 states and the District of Columbia in a lawsuit filed in early May.
DuBose said the states had shown 'irreparable harm,' from the cuts and were likely to prevail in their claims that the 'HHS's action was both arbitrary and capricious as well as contrary to law.'
'The executive branch does not have the authority to order, organize, or implement wholesale changes to the structure and function of the agencies created by Congress,' DuBose wrote in a 58-page order handed down in U.S. district court of Rhode Island.
Her order blocks the Trump administration from finalizing layoffs announced in March or issuing any further firings. HHS is directed to file a status report by July 11.
The ruling applies to terminated employees in four different divisions of HHS — the U.S. Centers for Disease Control and Prevention; the Center for Tobacco Products within the Food and Drug Administration; the Office of Head Start within the Administration for Children and Families and employees of regional offices who work on Head Start matters; and the Office of the Assistant Secretary for Planning and Evaluation.
Health Secretary Robert F. Kennedy Jr. eliminated more than 10,000 employees in late March and consolidated 28 agencies to just 15. Combined with previous layoffs by President Donald Trump's administration, about a quarter of the agency's workforce has been slashed, according to the lawsuit.
The attorneys general argued that the massive restructuring was arbitrary and outside of the scope of the agency's authority. The lawsuit also says the action decimated essential programs and pushed burdensome costs onto states.
'The intended effect … was the wholesale elimination of many HHS programs that are critical to public health and safety,' the lawsuit argued.
The cuts are part of a federal 'Make America Healthy Again' directive to streamline costly agencies and reduce redundancies. Kennedy told senators at a May 14 hearing that there is 'so much chaos and disorganization' at HHS.
But the restructuring has eliminated key teams that regulate food safety and drugs, as well as support a wide range of programs for tobacco, HIV prevention and maternal and infant health. Kennedy has since said that because of mistakes, 20% of people fired might be reinstated.
The states who joined the lawsuit have Democratic governors, and many of the same states — plus a few others — also sued the Trump administration over $11 billion in cuts to public health funding. A preliminary injunction was granted in that case in mid-May.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?

Yahoo

time29 minutes ago

  • Yahoo

Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering CVS Health (CVS), which belongs to the Zacks Medical Services industry. When looking at the last two reports, this drugstore chain and pharmacy benefits manager has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 32.64%, on average, in the last two quarters. For the last reported quarter, CVS Health came out with earnings of $2.25 per share versus the Zacks Consensus Estimate of $1.71 per share, representing a surprise of 31.58%. For the previous quarter, the company was expected to post earnings of $0.89 per share and it actually produced earnings of $1.19 per share, delivering a surprise of 33.71%. Thanks in part to this history, there has been a favorable change in earnings estimates for CVS Health lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. CVS Health has an Earnings ESP of +6.35% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #2 (Buy), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on July 31, 2025. With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss. Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate. Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

UnitedHealth Group (UNH) Stock Sinks As Market Gains: What You Should Know
UnitedHealth Group (UNH) Stock Sinks As Market Gains: What You Should Know

Yahoo

time29 minutes ago

  • Yahoo

UnitedHealth Group (UNH) Stock Sinks As Market Gains: What You Should Know

UnitedHealth Group (UNH) closed the most recent trading day at $307.56, moving -5.7% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.48% for the day. Elsewhere, the Dow lost 0.02%, while the tech-heavy Nasdaq added 0.94%. Shares of the largest U.S. health insurer witnessed a gain of 8.27% over the previous month, beating the performance of the Medical sector with its gain of 2.8%, and the S&P 500's gain of 5.13%. The investment community will be closely monitoring the performance of UnitedHealth Group in its forthcoming earnings report. The company is scheduled to release its earnings on July 29, 2025. The company's earnings per share (EPS) are projected to be $5.08, reflecting a 25.29% decrease from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $111.85 billion, indicating a 13.14% upward movement from the same quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $22.07 per share and a revenue of $449.46 billion, signifying shifts of -20.21% and +12.29%, respectively, from the last year. Investors should also pay attention to any latest changes in analyst estimates for UnitedHealth Group. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.54% lower. As of now, UnitedHealth Group holds a Zacks Rank of #4 (Sell). From a valuation perspective, UnitedHealth Group is currently exchanging hands at a Forward P/E ratio of 14.78. This indicates a premium in contrast to its industry's Forward P/E of 13.39. One should further note that UNH currently holds a PEG ratio of 1.55. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - HMOs industry had an average PEG ratio of 1.01 as trading concluded yesterday. The Medical - HMOs industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 34, finds itself in the top 14% echelons of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts
Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts

Yahoo

time29 minutes ago

  • Yahoo

Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts

Tenet Healthcare (THC) closed the most recent trading day at $172.22, moving -2.94% from the previous trading session. This change lagged the S&P 500's 0.48% gain on the day. On the other hand, the Dow registered a loss of 0.02%, and the technology-centric Nasdaq increased by 0.94%. Heading into today, shares of the hospital operator had gained 3.25% over the past month, outpacing the Medical sector's gain of 2.8% and lagging the S&P 500's gain of 5.13%. Market participants will be closely following the financial results of Tenet Healthcare in its upcoming release. The company plans to announce its earnings on July 22, 2025. The company is expected to report EPS of $2.84, up 22.94% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.15 billion, up 0.85% from the prior-year quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $12.73 per share and revenue of $20.9 billion, indicating changes of +7.15% and +1.12%, respectively, compared to the previous year. Any recent changes to analyst estimates for Tenet Healthcare should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.33% higher. Tenet Healthcare is currently a Zacks Rank #3 (Hold). In the context of valuation, Tenet Healthcare is at present trading with a Forward P/E ratio of 13.94. Its industry sports an average Forward P/E of 11.83, so one might conclude that Tenet Healthcare is trading at a premium comparatively. We can additionally observe that THC currently boasts a PEG ratio of 1.29. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Hospital industry was having an average PEG ratio of 1.32. The Medical - Hospital industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 37% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store